News >

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 13, 2019

Alessandra Tedeschi MD

Alessandra Tedeschi MD
The European Commission has expanded the approval of ibrutinib (Imbruvica) to include use in combination with obinutuzumab (Gazyvaro, EU; Gazyva, US) for adult patients with previously untreated chronic lymphocytic leukemia (CLL), and also in combination with rituximab (Rituxan) for the treatment of adult patients with Waldenström macroglobulinemia (WM).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x